Peter DiLaura is an accomplished biotechnology executive with over 20 years of experience in the life sciences industry. Driven by a passion for the role of emerging technologies in drug discovery, Peter’s career has spanned therapeutics, genomics platform technologies, systems biology, and data sciences.
Peter has been the CEO and a Director of Second Genome since 2010. During this time, the company has built a novel drug discovery platform for mining the microbiome for novel therapeutics, with programs in inflammation, metabolic disease, and immune regulation.
From 2001 to 2010, Peter held a range of commercial roles with increasing responsibility at Ingenuity Systems, a Bay Area systems biology company. Peter joined Ingenuity as the business development lead, grew revenue from zero to over $30 million per year, and ultimately managed a team of 40 people across sales, marketing, product management, and business development functions. Ingenuity was acquired by Qiagen (NASDAQ: QGEN) for $105 million in 2013.
Prior to Ingenuity Systems, Peter held roles at Chemdex/Ventro and IBM’s Health Care division. Peter began his career in life sciences as a strategy consultant in the New York office of The Wilkerson Group, where he worked for pharmaceutical, biotech, and venture capital clients on a range of strategic projects including portfolio development, competitive analysis, and investment diligence advisory.
Peter received a BS in Economics from the Wharton School at the University of Pennsylvania in 1995.
Karim Dabbagh leads the R&D organization at Second Genome. Prior to that, he led the immunoregulation department at Pfizer, an R&D group focused on innovative approaches to elicit homeostatic immune responses, including microbiome research, for the treatment of immune related disorders. At Pfizer, he also led external R&D innovation for autoimmune and inflammatory diseases. Past responsibilities include founding Modus BioMedicine, a start-up biotechnology company focused on treatments for transplantation and autoimmune disease, as well as spending nine years at Roche Pharmaceuticals in Inflammation Discovery Research. Dr. Dabbagh received his PhD in biochemistry from University College, London and his BS in biotechnology from the Imperial College of Science, Technology, and Medicine in London. He completed postdoctoral fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and at Stanford University where he worked on elucidating the role played by the microbiome in the hygiene hypothesis.
Mohan Iyer is Chief Business Officer of Second Genome. He started his career as a biochemical engineer at Genentech in the mid-80s, when the biotech industry itself was comprised of just a couple of start-ups. In a career spanning almost 30 years in biotech, he has held various executive level positions in both technical and business functions at several venture-backed companies with a focus on translating genomics, diagnostics, and personalized medicine. Outside of operating biotech companies, he has also been an investment banker and a management consultant, which further expands his industry perspective. He holds a BS in Chemical Engineering (Tennessee), an MS in Biomedical Engineering (Duke) and an MBA (Yale).
Todd DeSantis is Second Genome Co-founder and Senior Director of Bioinformatics. Todd has 17 years of experience designing and implementing bioinformatics solutions for analyzing microbial community dynamics. At Lawrence Berkeley National Laboratory he led the development of novel microbiome assays and analysis pipelines as a Molecular Microbial Ecology Software Developer. He is the chief architect of GreengenesTM, an international effort to catalog global microbial diversity that provides microbial ecologists with reference databases for DNA quality assessment, alignment and classification. Todd also served as an analyst for the NIH Human Microbiome Project and has published over 60 scientific papers. At Second Genome, he manages all informatics work including identifying and recruiting microbiome scientist leaders, integration of multi-omics pipelines, cloud deployment for big-data analytics, and therapeutic pathway discovery.